Becton Dickinson and Co (NYSE:BDX) has earned a consensus recommendation of "Hold" from the seventeen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $278.77.
A number of analysts have recently weighed in on the company. Goldman Sachs Group began coverage on Becton Dickinson and in a research note on Sunday, May 31st. They set a "buy" rating and a $278.00 price objective for the company. SVB Leerink increased their price objective on shares of Becton Dickinson and from $262.00 to $277.00 and gave the company a "market perform" rating in a research report on Wednesday, July 15th. Morgan Stanley decreased their price target on shares of Becton Dickinson and from $285.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 27th. Zacks Investment Research downgraded shares of Becton Dickinson and from a "hold" rating to a "sell" rating and set a $245.00 price target on the stock. in a research report on Wednesday, May 27th. Finally, Barclays upgraded shares of Becton Dickinson and from an "equal weight" rating to an "overweight" rating and set a $300.00 price objective on the stock in a research report on Thursday, July 9th.
In other Becton Dickinson and news, EVP Patrick Kaltenbach sold 1,272 shares of the firm's stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $260.00, for a total transaction of $330,720.00. Following the transaction, the executive vice president now directly owns 10,340 shares in the company, valued at approximately $2,688,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.12% of the company's stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Solstein Capital LLC acquired a new position in Becton Dickinson and in the first quarter worth about $27,000. Balentine LLC boosted its position in Becton Dickinson and by 45.3% during the 2nd quarter. Balentine LLC now owns 138 shares of the medical instruments supplier's stock worth $33,000 after acquiring an additional 43 shares during the period. Watson Rebecca acquired a new stake in shares of Becton Dickinson and during the 2nd quarter valued at about $36,000. Verus Capital Partners LLC lifted its holdings in shares of Becton Dickinson and by 65.0% during the 1st quarter. Verus Capital Partners LLC now owns 165 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 65 shares during the last quarter. Finally, Campbell Wealth Management bought a new position in shares of Becton Dickinson and in the 2nd quarter valued at approximately $42,000. 84.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of Becton Dickinson and stock opened at $226.15 on Wednesday. Becton Dickinson and has a one year low of $197.75 and a one year high of $286.72. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 0.97. The stock's 50-day moving average is $254.55 and its 200 day moving average is $247.51. The firm has a market cap of $68.38 billion, a price-to-earnings ratio of 81.35, a PEG ratio of 3.00 and a beta of 0.85.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.16. Becton Dickinson and had a return on equity of 14.19% and a net margin of 5.30%. The business had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the company earned $3.08 earnings per share. Becton Dickinson and's revenue was down 11.4% compared to the same quarter last year. On average, sell-side analysts expect that Becton Dickinson and will post 9.9 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $3.16 annualized dividend and a yield of 1.40%. Becton Dickinson and's payout ratio is currently 27.05%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: How to Profit and Limit Losses With Stop Orders
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 Stocks Analysts Can't Stop Upgrading
As you know, a single upgrade from a broker probably won't be a major game changer for any single stock. But, what if there was a stock that had been upgraded by more than 10 different brokers during the last 90 days?
If ten different brokers have all upgraded a stock within the last few months and the price hasn't skyrocketed (at least, not yet), you would want to take a pretty hard look at it.
It turns out that there are actually 20 different companies that have been upgraded or had their price target increased at least ten times during the last ninety days by more than 10 different brokers. This slideshow lists those companies.
View the "20 Stocks Analysts Can't Stop Upgrading".